Suppr超能文献

含菌发酵乳饮品治疗以便秘为主的肠易激综合征患者的临床评估和细胞因子水平。

Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink.

机构信息

Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur.

GUT Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur.

出版信息

Acta Gastroenterol Belg. 2021 Oct-Dec;84(4):585-591. doi: 10.51821/84.4.009.

Abstract

BACKGROUND

Gut dysbiosis is linked with the pathophysiology of irritable bowel syndrome (IBS). Manipulation of intestinal microbiota using cultured milk drinks may stimulate the immune system, hence providing beneficial support in IBS treatment. This study aimed to investigate the effects of cultured milk drink on clinical symptoms, intestinal transit time (ITT), fecal pH and cytokines in constipation-predominant IBS (IBS-C) as compared to non-IBS participants.

METHODS

Each recruited participant was given three bottles of 125 ml cultured milk drink containing 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01 consumed daily for 30 days. At pre- and post-30-day consumption, fecal pH, ITT, clinical symptoms, IL-6, IL-8 and TNF-α levels were assessed. Seventy-seven IBS-C and 88 non-IBS were enrolled.

RESULTS

Post-consumption, 97.4% of IBS-C experienced improvements in constipation-related symptoms supported by the significant reduction of ITT and decreased fecal pH (p<0.05). All pro-inflammatory cytokines were significantly lower in post as compared to pre-consumption of cultured milk drinks in IBS-C (p<0.05). There was significant reduction in the IL-8 and TNF-α levels in post- as compared to pre-consumption for the non-IBS (p<0.05).

CONCLUSION

Cultured milk drink taken daily improved clinical symptoms and reduced cytokines, hence should be considered as an adjunctive treatment in IBS-C individuals.

摘要

背景

肠道菌群失调与肠易激综合征(IBS)的病理生理学有关。使用发酵乳饮料来操纵肠道微生物群可能会刺激免疫系统,从而为 IBS 治疗提供有益的支持。本研究旨在调查发酵乳饮料对便秘型 IBS(IBS-C)与非 IBS 参与者的临床症状、肠道传输时间(ITT)、粪便 pH 值和细胞因子的影响。

方法

每位入组的参与者每天服用三瓶 125 毫升含 109 cfu 嗜酸乳杆菌 LA-5 和副干酪乳杆菌 L. CASEI-01 的发酵乳饮料,持续 30 天。在 30 天前和 30 天后,评估粪便 pH 值、ITT、临床症状、IL-6、IL-8 和 TNF-α 水平。共纳入 77 例 IBS-C 和 88 例非 IBS 患者。

结果

在摄入后,97.4%的 IBS-C 患者便秘相关症状得到改善,这得到了 ITT 显著降低和粪便 pH 值降低的支持(p<0.05)。与摄入发酵乳饮料前相比,IBS-C 患者摄入后所有促炎细胞因子均显著降低(p<0.05)。与摄入前相比,非 IBS 患者摄入后 IL-8 和 TNF-α 水平显著降低(p<0.05)。

结论

每天服用发酵乳饮料可改善临床症状并降低细胞因子水平,因此应考虑将其作为 IBS-C 患者的辅助治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验